Vis enkel innførsel

dc.contributor.authorSøraas, Arne Vasli
dc.contributor.authorGrødeland, Gunnveig
dc.contributor.authorGranerud, Beathe Kiland
dc.contributor.authorUeland, Thor
dc.contributor.authorLind, Andreas
dc.contributor.authorFevang, Børre
dc.contributor.authorMurphy, Sarah Louise Mikalsen
dc.contributor.authorHuse, Camilla
dc.contributor.authorNygaard, Anders Benteson
dc.contributor.authorSteffensen, Anne Katrine
dc.contributor.authorAl-Baldawi, Huda
dc.contributor.authorHolberg-Petersen, Mona
dc.contributor.authorAndresen, Lise Lima
dc.contributor.authorÅgnes, Camilla
dc.contributor.authorRanheim, Trine
dc.contributor.authorSchanke, Ylva
dc.contributor.authorIstre, Mette Stausland
dc.contributor.authorDahl, John Arne
dc.contributor.authorChopra, Adity
dc.contributor.authorDudman, Susanne
dc.contributor.authorKaarbø, Mari
dc.contributor.authorAndersen, Jan Terje
dc.contributor.authorVaage, Eline Benno
dc.contributor.authorTran, Trung The
dc.contributor.authorVaage, John Torgils
dc.contributor.authorMichelsen, Annika Elisabet
dc.contributor.authorMüller, Fredrik
dc.contributor.authorAukrust, Pål
dc.contributor.authorHalvorsen, Bente Evy
dc.contributor.authorDahl, Tuva Børresdatter
dc.contributor.authorHolter, Jan Cato
dc.contributor.authorLund-Johansen, Fridtjof
dc.date.accessioned2023-02-01T14:17:56Z
dc.date.available2023-02-01T14:17:56Z
dc.date.created2022-10-10T09:54:56Z
dc.date.issued2022
dc.identifier.citationFrontiers in Immunology. 2022, 13, Artikkel 964525.en_US
dc.identifier.issn1664-3224
dc.identifier.urihttps://hdl.handle.net/11250/3047786
dc.description.abstractBackground: Results showing that sera from double vaccinated individuals have minimal neutralizing activity against Omicron have been interpreted as indicating the need for a third vaccine dose for protection. However, there is little information about early immune responses to Omicron infection in double vaccinated individuals. Methods: We measured inflammatory mediators, antibodies to the SARS-CoV-2 spike and nucleocapsid proteins, and spike peptide-induced release of interferon gamma in whole blood in 51 double-vaccinated individuals infected with Omicron, in 14 infected with Delta, and in 18 healthy controls. The median time points for the first and second samples were 7 and 14 days after symptom onset, respectively. Findings: Infection with Omicron or Delta led to a rapid and similar increase in antibodies to the receptor-binding domain (RBD) of Omicron protein and spike peptide-induced interferon gamma in whole blood. Both the Omicron- and the Delta-infected patients had a mild and transient increase in inflammatory parameters. Interpretation: The results suggest that two vaccine doses are sufficient to mount a rapid and potent immune response upon infection in healthy individuals of with the Omicron variant.en_US
dc.language.isoengen_US
dc.publisherFrontiers Media S.A.en_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.subjectcellular immunityen_US
dc.subjectBreakthrough infectionen_US
dc.subjectantibodyen_US
dc.subjecthumanen_US
dc.subjectSARS-CoV-2en_US
dc.subjectvaccineen_US
dc.titleBreakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunityen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.rights.holder© 2022 Søraas, Grødeland, Granerud, Ueland, Lind, Fevang, Murphy, Huse, Nygaard, Steffensen, al-Baldawi, Holberg-Petersen, Andresen, Ågnes, Ranheim, Schanke, Istre, Dahl, Chopra, Dudman, Kaarbø, Andersen, Vaage, Tran, Vaage, Michelsen, Müller, Aukrust, Halvorsen, Dahl, Holter and LundJohansen.en_US
dc.subject.nsiVDP::Medisinsk mikrobiologi: 715en_US
dc.subject.nsiVDP::Medical microbiology: 715en_US
dc.source.volume13en_US
dc.source.journalFrontiers in Immunologyen_US
dc.identifier.doi10.3389/fimmu.2022.964525
dc.identifier.cristin2059925
dc.relation.projectNorges forskningsråd: 312780en_US
dc.relation.projectNorges forskningsråd: 324274en_US
dc.relation.projectHelse Sør-Øst RHF: 2019067, 2021071, 2021047, 33612, 2021087, 10357, 2017092en_US
dc.relation.projectEU – Horisont Europa (EC/HEU): 848099en_US
dc.relation.projectEU – Horisont Europa (EC/HEU): 71029en_US
dc.relation.projectOslo universitetssykehus HF: Fredrik Mülleren_US
dc.source.articlenumber964525en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal